By arming researchers with an in-depth toxicity and efficacy profile for candidate pipeline drugs, a new breed of models offer the prospect of saving drug developers millions. High potential compounds will be prioritized, animal use reduced and clinical strategy directed by progress in the predictive models field.
Realizing such immense potential will require thought leaders to address very specific challenges. Calls to action are being made to validate the utility and practicality of 3D culture, stem cell and organ-on-a-chip models and confront attendant issues in assay development. Industry and academia also agree that more must be done to productively integrate in vitro and in vivo acquired knowledge and translate that into clinical success.
By engaging with senior figures at Pfizer, Amgen, AstraZeneca, UCB, Novartis and many others, we have addressed these concerns and constructed an unbeatable agenda. As such, this meeting promises high level, commercially directed discussion of the most pressing technical and strategic issues at hand.
Attend this meeting to:
• Get an up-to-the-minute snapshot of cutting edge developments in in vitro models to boost preclinical accuracy and accelerate your drug discovery and development
• Avoid costly clinical attrition and maximize your profit by reducing development costs
• Understand the required criteria to achieve scientific validation of your model
• Benchmark yourself against industrial case studies on how in vitro models have performed in industry
• Meet the major industry players and most innovative start ups for unparalleled business development opportunities
• Increase efficiency by hearing from the leading solution providers and technology developers
Who should attend this meeting:
• Pharma companies interested in reducing drug development costs
• Scientists and academics working in tissue engineering, toxicology and systems biology
• Biotechs and solution providers developing exciting and innovative in vitro models
Further details and to register
